mda-7/IL-24 promotes both direct antitumor activity by inducing cancer-specific apoptosis as well as indirect antitumor activity by provoking anti-angiogenesis activity [12,13,14,15], in vitro and in vivo in preclinical animal models and in a Phase I clinical trial in patients with advanced cancers (includes breast carcinoma, colon carcinoma, squamous cell carcinoma of the head and neck, melanoma, large cell lymphoma, adrenal carcinoma, transitional cell carcinoma). This evidence concerns the gene IL24 and breast carcinoma.